Martin Cadeiras, MD
Cardiovascular Disease · Los Angeles, CANPI 1013152768
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,610 and has fallen 70.6% since, to $473 in 2025.
Across 77 payments — averaging $66.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novartis$727
- Abiomed$712
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$541
- E.r. Squibb & Sons, L.L.C.$298
- Alnylam Pharmaceuticals Inc.$244
- plus $2K from 16 others
Across 3 payments — averaging $15,707 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$47K
What the payments were for
- Food & beverage$5,01397%
- Education$1423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $1,056 |
| Novartis | 12 | $727 |
| Abiomed | 10 | $712 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $541 |
| E.r. Squibb & Sons, L.L.C. | 6 | $298 |
| Alnylam Pharmaceuticals Inc. | 3 | $244 |
| Actelion Pharmaceuticals US, Inc. | 3 | $219 |
| Boehringer Ingelheim | 2 | $183 |
| Pfizer | 7 | $181 |
| Novo Nordisk | 1 | $124 |
| Portola Pharmaceuticals, LLC | 1 | $124 |
| Getinge USA Sales, LLC | 2 | $124 |
| Cvrx, Inc. | 1 | $115 |
| Merck | 3 | $105 |
| AstraZeneca | 2 | $96 |
| Johnson & Johnson | 1 | $93 |
| Akcea Therapeutics, Inc. | 1 | $84 |
| Impulse Dynamics (USA) Inc. | 1 | $42 |
| Lexicon Pharmaceuticals, Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Recor Medical Inc | 1 | $18 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$498
- Impella$458
- ENTRESTO$261
- LEQVIO$261
- CARDIOMEMS$153
- ONPATTRO$125
- ANDEXXA$124
- LifeVest$119
- Barostim Neo System$115
- CARDIOHELP$113
- UPTRAVI$106
- ELIQUIS$103
- HeartMate 3 Left Ventricular Assist Device$102
How this compares
$5,154 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 44 | $990,862 |
| EntrestoSacubitril/Valsartan | 264 | $303,815 |
| JardianceEmpagliflozin | 186 | $217,678 |
| EliquisApixaban | 129 | $151,246 |
| OpsumitMacitentan | 12 | $131,083 |
| FarxigaDapagliflozin Propanediol | 73 | $78,820 |
| OzempicSemaglutide | 62 | $63,861 |
| XareltoRivaroxaban | 18 | $28,845 |
| WegovySemaglutide | 13 | $17,255 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $14,376 |
| Sildenafil Citrate | 17 | $9,123 |
| Metoprolol Succinate | 197 | $3,223 |
| Eplerenone | 36 | $3,045 |
| Bumetanide | 43 | $2,928 |
| Spironolactone | 206 | $2,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $181 | $1,142,108173 claims |
| NovartisEntresto | $727 | $303,815264 claims |
| Boehringer IngelheimJardiance | $183 | $217,678186 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $219 | $131,08312 claims |
| Novo NordiskOzempic, Wegovy | $124 | $81,11575 claims |
| AstraZenecaFarxiga | $96 | $78,82073 claims |
| Johnson & JohnsonXarelto | $93 | $28,84518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.